Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 60/100

Failure Rate

8.8%

67 terminated/withdrawn out of 763 trials

Success Rate

76.4%

-10.1% vs industry average

Late-Stage Pipeline

12%

92 trials in Phase 3/4

Results Transparency

2%

4 of 217 completed trials have results

Key Signals

45 recruiting4 with results29 terminated38 withdrawn

Enrollment Performance

Analytics

N/A
297(61.1%)
Phase 4
62(12.8%)
Phase 2
55(11.3%)
Phase 1
40(8.2%)
Phase 3
30(6.2%)
Early Phase 1
2(0.4%)
486Total
N/A(297)
Phase 4(62)
Phase 2(55)
Phase 1(40)
+2 more

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (763)

Showing 20 of 763 trials
NCT07401524Phase 4Recruiting

Carbetocin Uterotonic Treatment in Twin Pregnancies for Prevention of Postpartum Hemorrhage

Role: lead

NCT07546071Not ApplicableCompleted

Telemedicine-Based Emergency Physician Assessment Prior to ED Entry: A Randomized Controlled Trial

Role: lead

NCT04071704Completed

Assessing Health-related Quality of Life in Sarcoma Patients

Role: collaborator

NCT06654128Not ApplicableCompleted

The Yield of Artificial Intelligence (GI Genius) in Lynch Syndrome - A Randomized Tandem-colonoscopy Trial

Role: lead

NCT05199324Phase 4Recruiting

Early Oral Switch for Uncomplicated Gram-negative Bacteraemia

Role: collaborator

NCT07405723Not ApplicableRecruiting

Arm Position and Blood Pressure Measurement Accuracy During Pregnancy

Role: lead

NCT07523373Not ApplicableNot Yet Recruiting

Facial Nerve Monitoring During Parotid and Facial Surgery Using a Non-Invasive Patch

Role: lead

NCT05908708Recruiting

Closed-loop Medtronic 780G System in Youth With Type 1 Diabetes

Role: lead

NCT07474987Recruiting

Portable VR-based Chromatic Pupilloperimeter for Diagnosis and Monitoring of Traumatic Brain Injury

Role: lead

NCT07503353Phase 1Not Yet Recruiting

A Phase 1/2 Study of T-cell Expressing a Novel CD19 Chimeric-Antigen Receptor (SHB-02-CD19) in Patients With CD19-expressing B-cell Malignancies

Role: lead

NCT07469098Phase 2Recruiting

Group vs Individual MDMA-Assisted Therapy for PTSD After the October 7, 2023 Events

Role: lead

NCT06087757Phase 2Active Not Recruiting

Clemastine Treatment in Individuals With Williams Syndrome

Role: lead

NCT07430501Not Yet Recruiting

Using Digital Twin Technology and Clinical Decision Support Systems to Improve the Early Detection, Personalised Treatment, and Long-term Monitoring of Patients Across the Full Spectrum of Metabolic-associated Fatty Liver Disease (MAFLD).

Role: collaborator

NCT06350669Not ApplicableCompleted

App-supported Vestibular Rehabilitation (RCT)

Role: collaborator

NCT07399756Not Yet Recruiting

Mitochondrial Function After Ketamine

Role: lead

NCT06625112Recruiting

A Multicentric European Study to Promote Clinical Trial Readiness for STXBP1-related Disorders

Role: collaborator

NCT07118280Recruiting

Oral Health, Saliva Viscosity and Composition in Oculo-Pharyngeal Muscular Dystrophy (OPMD)

Role: lead

NCT07135466Phase 1Recruiting

A Phase 1/2 Study of T-cell Expressing an Anti-CD22 Chimeric-Antigen Receptor (SHB-04-CD22) in Patients With CD22-expressing B-cell Malignancies

Role: lead

NCT07327021Phase 2Recruiting

MRI-Guided Neoadjuvant Treatment De-Escalation in Stage II-III TNBC

Role: collaborator

NCT07328061Not ApplicableCompleted

Virtual Reality for Anxiety and Pain Management in Transvaginal Ultrasound for Endometriosis

Role: lead